Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report

The administration of intravesical chemotherapy or BCG often can prolong the progression-free interval after initial transurethral resection in select bladder cancer (BCa) patients. However, 60% of these patients will recur and up to 30% of patients with recurrent BCa will progress and succumb to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jeffrey, Schisler, John, Wong, Hing C., Rosser, Charles J., Sterbis, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466554/
https://www.ncbi.nlm.nih.gov/pubmed/28607879
http://dx.doi.org/10.1016/j.eucr.2017.04.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466554/
https://www.ncbi.nlm.nih.gov/pubmed/28607879
http://dx.doi.org/10.1016/j.eucr.2017.04.015

Ejemplares similares